|2011.12.18||ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes – Expected Launch in Q2 2012
YOKOHAMA, Japan, December 15, 2011 – ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug screening for hepatic toxicity and liver metabolism using hepatocytes derived from human iPS cells since early this year. Together with NIBIO, the company successfully established the hepatocytes which highly express active drug metabolizing enzyme. Currently, the company is evaluating the system using various drugs with pharmaceutical companies to observe how the drugs are metabolized. ReproCELL […]
|2011.12.05||PRODUCTReproHepato web page launched
Information about ReproHepato 3A4, a human iPSC-derived hepatocyte product, is now available on ReproCELL website. Updated information will be added continuously so please check the web page often. The product will be launched in Spring 2012. ReproHepato 3A4 web page Inquiry about ReproHepato 3A4
|2011.09.27||PRODUCTNew Product: ReproCardio 2 (human iPSC-derived cardiomyocytes, frozen)
ReproCELL launches its second iPSC-cardiomyocyte product ReproCardio 2. Since the world’s first launch of the first version product (ReproCardio), ReproCELL has been continuously improving the products and now established frozen cells as a product. ReproCardio 2 contains natural population of human heart cells which are necessary for efficient prediction of compound effects in the drug development process. Please visit ReproCardio 2 product website to learn about it.
|2011.04.18||PRODUCTNew product: Feeder-free medium ReproFF2
ReproCELL announces launch of a new product ReproFF2. ReproFF2 is a new feeder-free medium which doesn’t require everyday medium change while keeping the cells in a good condition without feeder cells. For more information please visit the product web page.
|2011.01.05||ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes
ReproCELL announces today that it will start a collaboration with the National Institute of Biomedical Innovation (NIBIO) to develop human iPS cell-derived hepatocytes for in vitro drug screening, hepatic toxocity and drug metabolism. See the news